Daud A - Search Results

1

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Niu G, et al. Among authors: daud a. Oncogene. 2002 Oct 10;21(46):7001-10. doi: 10.1038/sj.onc.1205859. Oncogene. 2002. PMID: 12370822

2

Activated stat-3 in melanoma.

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Messina JL, et al. Cancer Control. 2008 Jul;15(3):196-201. doi: 10.1177/107327480801500302. Cancer Control. 2008. PMID: 18596671 Free article.

3

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. Homsi J, et al. Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c. Melanoma Res. 2009. PMID: 19434004

4

Immunotherapy as part of a multidisciplinary approach to melanoma treatment.

Riker AI, Jove R, Daud AI. Riker AI, et al. Front Biosci. 2006 Jan 1;11:1-14. doi: 10.2741/1775. Front Biosci. 2006. PMID: 16146709 Review.

5

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Khan MA, et al. Cancer Control. 2006 Jul;13(3):211-7. doi: 10.1177/107327480601300308. Cancer Control. 2006. PMID: 16885917 Free article.

6

The Src signaling pathway: a potential target in melanoma and other malignancies.

Homsi J, Cubitt C, Daud A. Homsi J, et al. Among authors: daud a. Expert Opin Ther Targets. 2007 Jan;11(1):91-100. doi: 10.1517/14728222.11.1.91. Expert Opin Ther Targets. 2007. PMID: 17150037 Review.

7

Cutaneous melanoma: prognostic factors.

Homsi J, Kashani-Sabet M, Messina JL, Daud A. Homsi J, et al. Among authors: daud a. Cancer Control. 2005 Oct;12(4):223-9. doi: 10.1177/107327480501200403. Cancer Control. 2005. PMID: 16258493 Free article. Review.

8

Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma.

Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Jensen EH, et al. Among authors: daud a. Ann Surg Oncol. 2007 Apr;14(4):1416-23. doi: 10.1245/s10434-006-9226-2. Epub 2006 Dec 30. Ann Surg Oncol. 2007. PMID: 17195911

9

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.

Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. Puzanov I, et al. Among authors: daud a. JAMA Oncol. 2020 Aug 1;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288. JAMA Oncol. 2020. PMID: 32672795 Free PMC article. Clinical Trial.

10

Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma.

Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Finkelstein SE, et al. Among authors: daud a. J Immunother. 2010 Oct;33(8):817-27. doi: 10.1097/CJI.0b013e3181ecccad. J Immunother. 2010. PMID: 20842055 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

425 results

Search Page

Filters